Astellas Venture Management

Astellas Venture Management

A Menlo Park-based venture capital firm that invests in companies within the biotechnology sector

Astellas Venture Management is a venture capital firm in Menlo Park that prefers to invest in companies within the biotechnology sector. Founded 1999 in Menlo Park, California, the firm invests in early stage ventures, late stage ventures, and private equity. The notable investment portfolio of Astellas Venture Management includes TScan Therapeutics, Heartseed, CODA Biotherapeutics, Oncorus, Cleave Therapeutics, Twentyeight-Seven Therapeutics, Effector Therapeutics, and Oncorus. As of January 2020, Astellas Venture Management has made 41 investments and 9 exits. Their most recent investment was on Jan 10, 2020, when TScan Therapeutics raised $35M.

Timeline

1999

Founded

Funded Companies

Company
Description
Industry
Website
Location
Fate Therapeutics

A company developing therapies for the treatment of cancer and immune disorders

A biopharmaceutical company focused on the discovery and development of epigenetic medicines to treat cancer and other disease

A biopharmaceutical company that develops drugs for the treatment of cardiovascular diseases, endocrine and other metabolic disorders

A company dedicated on the discovery and development of small molecule therapeutics to treat cancer

A biopharmaceutical company that develops therapeutics to treat cancer

A company developing biologically active compounds and drug candidates

A biotechnology company developing peptides and antibodies for inflammation and autoimmunity

A biotechnology company that develops RNA interference therapeutics

A company developing Innate Defense Regulators

Twentyeight-Seven is a biomedical startup with a passion for cutting-edge life saving technology.

A company developing antifungal therapies

Oncorus is a Cambridge, Massachusetts-based company.

F2G is a biotechnology company.

Cleave Biosciences is a Burlingame, California-based company.

18 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Takashi Futami

Associate Investment Director

Ken Shimokawa

Senior Investment Director

Makoto Ohori

Investment Director

Sakae Asanuma

President & Chief Executive Officer

Takatoshi Soga

Associate Investment Director

Taro Masunaga

Investment Director

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Cleave Therapeutics

Twentyeight-Seven Therapeutics

CODA Biotherapeutics

Effector Therapeutics

Heartseed

Oncorus

TScan Therapeutics

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.